↓ Skip to main content

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001

Overview of attention for article published in Gynecologic Oncology Research and Practice, July 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)

Mentioned by

news
8 news outlets
twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
60 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001
Published in
Gynecologic Oncology Research and Practice, July 2017
DOI 10.1186/s40661-017-0047-8
Pubmed ID
Authors

Brett Miles, Howard P. Safran, Bradley J. Monk

Abstract

Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacterial vector Listeria monocytogenes (Lm) activates innate and adaptive immune responses and is expected to offer immunologic advantages. Axalimogene filolisbac (AXAL or ADXS11-001) is a novel immunotherapeutic based on the live, irreversibly attenuated Lm fused to the nonhemolytic fragment of listeriolysin O (Lm-LLO) and secretes the Lm-LLO-HPV E7 fusion protein targeting HPV-positive tumors. Herein are reported the development and recent results of various clinical trials in patients with HPV-associated cervical, head and neck, and anal cancers.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 60 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 13%
Student > Master 8 13%
Student > Ph. D. Student 7 12%
Student > Bachelor 7 12%
Student > Postgraduate 4 7%
Other 10 17%
Unknown 16 27%
Readers by discipline Count As %
Medicine and Dentistry 16 27%
Biochemistry, Genetics and Molecular Biology 11 18%
Immunology and Microbiology 7 12%
Agricultural and Biological Sciences 2 3%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Other 5 8%
Unknown 17 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 64. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2022.
All research outputs
#634,675
of 24,586,986 outputs
Outputs from Gynecologic Oncology Research and Practice
#4
of 35 outputs
Outputs of similar age
#13,617
of 316,944 outputs
Outputs of similar age from Gynecologic Oncology Research and Practice
#2
of 3 outputs
Altmetric has tracked 24,586,986 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 35 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.9. This one scored the same or higher as 31 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,944 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.